Search results

Assay proposed for the measurement of TAFI in research applications.

Quality control of clotting assays proposed for measuring argatroban concentrations in plasma (especially ref. CK002K, CK002L).

Calibrating the assays of argatroban using clotting anti-IIa methods, especially when the HEMOCLOT Thrombin Inhibitors kit (ref. CK002K, CK002L) is used, with the low range protocol.

Quantitative measurement of dabigatran, and anti-thrombin activities in plasma (e.g. Dabigatran Plasma Calibrator (ref. 222801), Dabigatran Control Plasma (ref. 224701), Argatroban Plasma Calibrator (ref. SC030K), Argatroban Control Plasma (ref. SC035K)).

Quantitative measurement of dabigatran, and anti-thrombin activities in plasma (e.g. Dabigatran Plasma Calibrator (ref. 222801), Dabigatran Control Plasma (ref. 224701), Argatroban Plasma Calibrator (ref. SC030K), Argatroban Control Plasma (ref. SC035K)).

Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.

Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.

Chromogenic substrate for thrombin.

Quantitative measurement of Factor V Leiden, resistant to the action of activated protein C (APC resistance), for diagnosing patients carrying the R506Q FV mutation (Factor V Leiden), or any FV mutant resistant to APC.

Assay proposed for the measurement of anti-IIa activity in research applications.